Answering Critics of Pharmaceutical Patents
by Merrill Matthews on 02/06/2003
2 Pages
Synopsis:
Of all the recent criticisms leveled at the prescription drug industry, the one that has resonated most is that drug companies are gaming the patent system. However, the Hatch-Waxman Act that governs the role between generics and brand name drugs is very complicated, and it has ultimately weakened intellectual property protections. It is naive to assume that branded companies are sidestepping the rules while generics always play fair.
If you did not arrive at this web page from within the IPI website, click on the link below to go to IPI:
Note: PDF denotes that the document is in Adobe Acrobat PDF format. This is the preferred format for printing and viewing IPI publications; however, you'll need the free Adobe Acrobat Reader program. We suggest obtaining the program and installing it as a browser plug-in at http://www.adobe.com.